Fundraising Fox
Oncotarget
Founded 2010 · 6 employees on LinkedIn · 1 known investors
Find your way into Oncotarget
Sign up to find every way you can get introduced to Oncotarget
- Your email: who you already know at Oncotarget, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Oncotarget team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Oncotarget is a peer-reviewed academic journal publishing oncology and cancer research papers, indexed in databases such as PubMed, MEDLINE, and Scopus. It is operated by Rapamycin Press LLC (dba Impact Journals) and serves researchers and investigators in cancer research and medicine.
Founders & leadership
WS
Wafik S. El-DeiryCo-Editor-in-ChiefHe is the Mencoff Family Endowed University Professor of Medical Science and a tenured Professor of Pathology and Laboratory Medicine at Brown University, where he founded and led the Legorreta Cancer Center and the Joint Program in Cancer Biology and now serves as Director Emeritus of the Cancer Center. He is also pursuing a Physician MBA at the Kelley School of Business, with an expected graduation in 2028.
Investors · 1
Frequently asked questions
- What does Oncotarget do?
- Oncotarget is a peer-reviewed academic journal publishing oncology and cancer research papers, indexed in databases such as PubMed, MEDLINE, and Scopus. It is operated by Rapamycin Press LLC (dba Impact Journals) and serves researchers and investigators in cancer research and medicine.
- Who are Oncotarget's investors?
- Oncotarget's investors include Compound.